PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Sara Hurvitz, MD - Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.